Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Summary

This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2019-03-14

Primary completion

2021-10-22

Completion

2021-10-22

Outcome

Outcome not reported

Stopped (Enrollment): “it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.”

Drugs

Indications